Optimising vaccine follow-up through early planning

With increasing demand for longitudinal vaccine safety and efficacy data, driven by shifting regulatory requirements and public expectations, planning for long-term follow-up is critical for vaccine developers. One invaluable tool for enabling long-term follow-up is clinical trial tokenisation, which leverages anonymised tokens and real-world data (RWD) to continue gathering information on participant health after the conclusion of clinical trials.

To achieve the greatest possible benefits from tokenisation, including increased data access and streamlined operations, sponsors must begin planning for long-term follow-up early in the development process. This whitepaper discusses the role of patient tokenisation in vaccine follow-up and the importance of early planning, considerations for long-term follow-up design, and elements of ensuring secure long-term follow up.

• When to plan for long-term follow-up
• The role of clinical trial tokenisation in follow-up
• The benefits of early planning for long-term follow-up
• How to determine the best approach for a trial’s needs
• Strategies for collecting data on long-term effectiveness
• Considerations to ensure secure, regulatory-compliant data practices